Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 17 Publications

5 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

  • Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

  •  

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

  • Intracellular ratio between reduced and oxidized glutathione of the indicated cells treated with oxaliplatin or irinotecan for 6h was measured with spectrophotometric analysis.

    Theranostics, 2018, 8(5): 1312–1326. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MX3DfZRwfG:6aXPpeJkhSXO|YYm= MlHJNQKBmzF4MNMg{txO Ml2xOFjDqGh? M3XDPGlEPTB;NT64xsDDucLiMD61JO69VQ>? MoqwNlY1PzR4OUO=
CaES-17 MVvDfZRwfG:6aXPpeJkhSXO|YYm= NEX3dXEx6oDVMU[wxsDPxE1? M{\QV|Q5yqCq NGmzbWJKSzVyPUWuOeKhyrIEoECuNkDPxE1? NGnlPGEzPjR5NE[5Ny=>
SW480 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe0PEBpyqB? NVPhTHJCUUN3ME2xMlg4KM7:TR?= MXSyOlI3QTd3OR?=
HCT116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVOIc1QCCqwrC= MYnJR|UxRTFzLki2JO69VQ>? NGDw[XMzPjJ4OUe1PS=>
LoVo NYHxWJpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrsOFghcMLi M{TCd2lEPTB;OUSuPFMh|ryP MUCyOlI3QTd3OR?=
SK-BR-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnndmNrUUN3ME2zNU4xKMLzIECuNUDPxE1? NXLZ[4E5OjZ{MUG1PVE>
MCF-7 MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHwTWM2OD1zNT60JOKyKDBwMzFOwG0> MmD4NlYzOTF3OUG=
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ|LkGgxtEhOC5zIN88US=> NGO3OHEzPjJzMUW5NS=>
HCT116 p53+/+ NX:wTId6TnWwY4Tpc44hSXO|YYm= M{XR[lEwPSEQvF2= NWi5V2c{OjRxNEigbC=> M{\CN4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= MYOyOlIxQDV{Mx?=
LoVo  NVHHcYo3TnWwY4Tpc44hSXO|YYm= MWqxM|Uh|ryP MmP5NlQwPDhiaB?= NFW1OndqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O NVPPS|lqOjZ{MEi1NlM>
SNU-398 NIDsc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTZwNdMgxtHDqDFwMTFOwG0> NIfCdXIzPjF4MESyPS=>
Hep-G2 NUHnOGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn62TWM2OD1zMz6xxsDDucLiMT62JO69VQ>? MWeyOlE3ODR{OR?=
SNU-475 M1HqWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\ZbmlEPTExvK6zNEDPxE1? MXWyOlE3ODR{OR?=
SNU-387 M3W2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H0d2lEPTB;MkZCpOKyyqB{Lkeg{txO M4XNO|I3OTZyNEK5
HT29 NVPoZ4pPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniyTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? M2j3SFI3OTR6NUm2
HCT116 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmycFI2UUN3ME2wMlQyyqEEsdMgNE4xOiEQvF2= MlPWNlYyPDh3OU[=
PA-1 M1GwXGNmdGxiVnnhZoltcXS7IFHzd4F6 MVewMVIxKM7:TR?= MlHHNlQwPDhiaB?= M1TBW4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MnrZNlYyOzh4N{G=
OVCAR-5 Mk\LR4VtdCCYaXHibYxqfHliQYPzZZk> NWHUdYtZOC14MDFOwG0> MormNlQwPDhxN{KgbC=> NUXHbGdwcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M{\sZ|I3OTN6Nkex
SK-OV-3 MoOxR4VtdCCYaXHibYxqfHliQYPzZZk> NFXWeGwxNTFyMDFOwG0> NF\uN4YzPC92OD:3NkBp MnLzbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= M1u5NlI3OTN6Nkex
PA-1 MoW1SpVv[3Srb36gRZN{[Xl? MXexNEDPxE4EoB?= Mo\YNlRp NG\ac2t1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> MmDFNlYyOzh4N{G=
OVCAR-5 MX;GeY5kfGmxbjDBd5NigQ>? Mo\3N|Ah|ryP M2DJd|Q5cA>? M{fkbZRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NYCweVRbOjZzM{i2O|E>
SK-OV-3 NFOxW2pHfW6ldHnvckBCe3OjeR?= Mn7hOVAh|ryP MVW5OkBp M3jufZRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NE\UeZEzPjF|OE[3NS=>
PA-1 M4rkeWZ2dmO2aX;uJGF{e2G7 MYSxNEDPxE4EoB?= NITCRVM1QGh? NH2xR3N2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? MknFNlYyOzh4N{G=
OVCAR-5 NVz2VJBzTnWwY4Tpc44hSXO|YYm= MnnjN|Ah|ryP MY[0PIg> NF[3Uo12eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NWfiXVRROjZzM{i2O|E>
SK-OV-3 M3HSWmZ2dmO2aX;uJGF{e2G7 NEnBdnE2OCEQvF2= NInTeFE6PiCq NFzyXYJ2eC2{ZXf1cIF1\XNidHjlJJN1emW|czDsbYdidmS|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN? NIT1UpIzPjF|OE[3NS=>
PA-1 MUXGeY5kfGmxbjDBd5NigQ>? NWDnSZV[OTBizszNxsA> NGf5UGYzPGh? M1ftdpBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz NWfGdXd[OjZzM{i2O|E>
OVCAR-5 MYXGeY5kfGmxbjDBd5NigQ>? M3LsdVIxKM7:TdMg NYXRcm1lOjSq MV3wdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= M1\qTFI3OTN6Nkex
SK-OV-3 M{m5O2Z2dmO2aX;uJGF{e2G7 NXjJOI1{PTBizszNxsA> MnPwOFghcMLi NHPwfZpxem:vb4Tld{B{\W6|aYTpeol1gSCxZjDveoFzcWGwIHPhdoNqdm:vYTD0c{BPUyClZXzsMY1m\GmjdHXkJIN6fG:ueYPpdy=> NEfo[WUzPjF|OE[3NS=>
CT26  M1n2fGZ2dmO2aX;uJGF{e2G7 NXezeVBGPCCvTR?= MmLSOFghcMLi NEH5WZNqdmS3Y3XzJIF2fG:yaHHnfS=> NWfUN5k3OjZzM{ewNVI>
CT26  MUjGeY5kfGmxbjDBd5NigQ>? NIXLTWY1KG2P MlrhOFghcMLi M4rZcIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3 MnTiNlYyOzdyMUK=
CT26  M1H2NWNmdGxiVnnhZoltcXS7IFHzd4F6 MnrXOEBuVQ>? M3LQNVQ5KGkEoB?= MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? M1S0PVI3OTN5MEGy
BE M37qNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnBO5dmUUN3ME2zMlM{KM7:TR?= NWnPOotJOjZyMkOwPFU>
Colo205 NVn5VmFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv1NZVKSzVyPUOuN|Mh|ryP M1vOblI3ODJ|MEi1
DLD1 NYrhclY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTJwMEGg{txO NWWwWos5OjZyMkOwPFU>
HT29 NWDpT|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDFTWM2OD1{Lk[5JO69VQ>? NInTdYQzPjB{M{C4OS=>
HCT15 NVXtfGVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nTd2lEPTB;MT60N{DPxE1? NFnSSI4zPjB{M{C4OS=>
HCT116 NHPVNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOzfoRpUUN3ME2xMlA1KM7:TR?= NHrFeXAzPjB{M{C4OS=>
HCT116p53- NXzuSlRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTFwMEig{txO M3;YU|I3ODJ|MEi1
KM12 NFTrV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vnNmlEPTB;ND6zO{DPxE1? Ml7VNlYxOjNyOEW=
LoVo MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNdFY5UUN3ME2xMlIh|ryP MlPUNlYxOjNyOEW=
RKO NFW1eWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HxRWlEPTB;MT6yN{DPxE1? NVS4OVdSOjZyMkOwPFU>
SW480 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnQTWM2OD1{Lki2JO69VQ>? M1rtUVI3ODJ|MEi1
SW620 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1|Lk[4JO69VQ>? NFPuenkzPjB{M{C4OS=>
MC38 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTJ|IN88UUDDuSB{ MnTCNlYxODRyOES=
HT29 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG5TWM2OD14MzFOwG0hyrFiMUi= MWiyOlAxPDB6NB?=
DLD-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK2[4xoUUN3ME2zNk4zKM7:TR?= NFnIR2IzPjByM{C4OS=>
HT-29 Ml7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXzfZRRUUN3ME2zOU43KM7:TR?= NV36ZYZFOjZyMEOwPFU>
SiHa M3fNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH6PHBxUUN3ME2wMlghyrFiMD6xJO69VQ>? NUjDNYszOjV6MEGwNFc>
S3 Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nYR2lEPTB;NUOuOUDDuSBzLkWg{txO NF7wOlkzPThyMUCwOy=>
AGS NF3Bd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\sTZZjUUN3ME2xNE43KM7:TR?= NVjzPXZ[OjV5OEmwOVc>
MKN-45 M3rCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTF2LkCg{txO NEK1eGMzPTd6OUC1Oy=>
TMK-1 NYPycJZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13TSGlEPTB;MkKuOkDPxE1? NUP1emJ5OjV5OEmwOVc>
SCM-1 NV2zVFFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7nTWM2OD1zNz61JO69VQ>? M13BV|I2Pzh7MEW3
HCT-15 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwNkSg{txO M4LrOFI2PzZzNEe5
DiFi M1zESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTFyLkm1JO69VQ>? NF3IPJMzPTd4MUS3PS=>
DLD-1 MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT6UYZTUUN3ME24MlY2KM7:TR?= NFHzU5EzPTd4MUS3PS=>
COLO-320DM NWrHUIJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVwM{ig{txO NH3aVWMzPTd4MUS3PS=>
SNU-175 M1LGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG2TGZNUUN3ME2xMlUyKM7:TR?= MVSyOVc3OTR5OR?=
HT-29 NIXpTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHLdIFGUUN3ME21MlIzKM7:TR?= M2GxU|I2PzZzNEe5
SW620 M3jFdGZ2dmO2aX;uJGF{e2G7 NXvuTHF4OTEkgJpCuYcwdWx? NXLTenNtOjUkgJno NWTYeY54cW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= MYKyOVc1QTR{MB?=
SW480 M1vrN2Z2dmO2aX;uJGF{e2G7 NY\SV5M5OTEkgJpCuYcwdWx? M1zlOVI16oDLaB?= Mn\UbY5kemWjc3XzJGxEOy2LSTDhZ4N2dXWuYYTpc44h[W6mIHTlZ5Jm[XOnczDQOlIh\XiycnXzd4lwdg>? M{\tPVI2PzR7NEKw
SW620 MYjGeY5kfGmxbjDBd5NigQ>? Mk\mNVDjiIoEtXevcYw> MoG2NlTjiImq Mn3q[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 NY\uTnBIOjV5NEm0NlA>
SW480 MknQSpVv[3Srb36gRZN{[Xl? NVy4O3RnOTEkgJpCuYcwdWx? NIHYN|UzPOLCiXi= MVnlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MkDsNlU4PDl2MkC=
A549 MmDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\JZWlEPTB;NT64JOKyKDBwNjFOwG0> MYCyOVYzPTJ2Mx?=
A549/CDDP NED0R|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;3TWM2OD1zOD62JOKyKDFwMjFOwG0> MWWyOVYzPTJ2Mx?=
Panc-1 NEf0dnBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3HmWlI2NzVyIN88US=> M2HZeFI1NzR6IHi= MVrpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NGjOV5MzPTR2NEmxOC=>
MIAPaCa-2 Mkn6R4VtdCCYaXHibYxqfHliQYPzZZk> M3nXXVI2NzVyIN88US=> MV:yOE81QCCq Mn;xbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC M3rHU|I2PDR2OUG0
SW1990 MkX0R4VtdCCYaXHibYxqfHliQYPzZZk> M3HUTFI2NzVyIN88US=> NHO2SGczPC92ODDo NVvkO3B4cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M{nicFI2PDR2OUG0
HPDE MmLIR4VtdCCYaXHibYxqfHliQYPzZZk> NFTmelAzPS93MDFOwG0> MljHNlQwPDhiaB?= M4HyWYlvcGmkaYTzJJBzd2yrZnXyZZRqd25ib3[gVGMh[2WubIOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? MX[yOVQ1PDlzNB?=
Panc-1 NGraU|hCeG:ydH;zbZMhSXO|YYm= NWKxO5Z{OjYkgJpCuW0> Ml3sNlQhcA>? MoPRbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M1fV[FI2PDR2OUG0
MIAPaCa-2 M1y1OGFxd3C2b4Ppd{BCe3OjeR?= NUPPWYs3OjYkgJpCuW0> MX:yOEBp NG[5dHhqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD NH;WeIczPTR2NEmxOC=>
Panc-1 MnnLSpVv[3Srb36gRZN{[Xl? M1G5eFI26oDLwsXN MVyyOE81QCCq NXOwNmI1cW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> NVXm[4NiOjV2NES5NVQ>
MIAPaCa-2 M2\6W2Z2dmO2aX;uJGF{e2G7 MVWyOgKBkcL3TR?= NEHPSJIzPC92ODDo NVP3V|hHcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> M1jMXlI2PDR2OUG0
SW480 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\4O|IhcMLi M4iyW2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx? MoeyNlU{PjB4M{G=
HCT116  MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPhO|IhcMLi NVPL[ZFxUUN3ME22MlI{yrFyLke1JOK2\y:vTB?= NGiweZYzPTN4ME[zNS=>
COC1 NVPzZ5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\le3V{UUN3ME20Ok4zOMLiwsJCpFMvOTRizszN NGTjTm4zPTNyN{S0PC=>
SGC7901 NWPu[Wt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjkTWM2OD1{MT63N:KhyrIEoEOuNFgh|ryP NHHpVpYzPTNyN{S0PC=>
A549 NGe0elJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f3bGlEPTB;NUGuNFjDqMLzwrCxNE46PiEQvF2= MkXaNlU{ODd2NEi=
HepG2 Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LidmlEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= MojvNlU{ODd2NEi=
MCF-7 NVnDcHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF2LkK0xsDDucLiMT64NkDPxE1? NXzjOGpLOjV|MEe0OFg>
HCT-116 NGjWT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjWcIdKSzVyPU[uNlTDqMLzwrCyMlk4KM7:TR?= MoLDNlU{ODd2NEi=
HT-29 Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPNOI5KSzVyPkWwJO69VQ>? MoPDNlU{ODd2NEi=
HEK293 NULiS3J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrETWM2OD16LkiyxsDDucLiNT61PUDPxE1? NWfnRVFoOjV|MEe0OFg>
HUVEC M4LIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\HTWM2OD1zMT6zNOKhyrIEoEGuNFIh|ryP NYHncVZlOjV|MEe0OFg>
SW480 NUG5dJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmxxsDPxE1? MYCwMVczKGh? MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NGXsdWIzPDl7N{S1NS=>
HT-29 NXKyNmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXuxxsDPxE1? M1WwTVAuPzJiaB?= MoTBbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NInMZm8zPDl7N{S1NS=>
HCT116 NYnJfo5tTnWwY4Tpc44hSXO|YYm= NGT0TIkzNzViwsXN MUKyOE81QCCq MmXud5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36= MXGyOFc3OTRzMR?=
SW480  M4X4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojLOFghcMLi NE\QeJRKSzVyPUKwMlghfWdxbVy= M3jNVlI1PzJyNke1
SW620 M17FTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknLNVAuPzBibXevUC=> NYXFXmZ1OjRxNEivO|IhcA>? NEjL[3RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M4jt[lI1PjR4M{C1
Caco2  NIH3boJHfW6ldHnvckBCe3OjeR?= NVH0VJdXOzEEoN88US=> NYr1XGt6OjRiaB?= NViyNFd3TE2VTx?= M1vNSIlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gTG8uOSxiQVvSNWMtKGGwZDDOVW8y MYWyOFU2PjRzNR?=
Caco2  NYWzOHB1TnWwY4Tpc44hSXO|YYm= NIXnPZo{NzFyL{OwJO69VQ>? MVqxOkBp NEjZcHBFVVOR MlLnbY5kemWjc3XzJJRp\SCvUl7BJIxmfmWuczDv[uKhSUuUMVOxMEBPWU9zLDDIU{0yNCCPUmCyMOKh[W6mTWLQN:Kh\G:|ZT3k[ZBmdmSnboTsfS=> NGnDeJEzPDV3NkSxOS=>
Caco2 MnrOSpVv[3Srb36gRZN{[Xl? M{HLVVMxNzFyMNMg{txO NHXzUG4yPsLiaB?= M1jUbmROW09? MVjhZ5RqfmG2ZYOgUpJnOg>? MW[yOFU2PjRzNR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
in solvent
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03784326 Not yet recruiting Clinical Stage II Esophageal Adenocarcinoma AJCC v8|Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Clinical Stage III Esophageal Adenocarcinoma AJCC v8|Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage II Esophageal Adenocarcinoma AJCC v8|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage III Esophageal Adenocarcinoma AJCC v8|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8|Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Early Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03626922 Not yet recruiting Metastatic Colorectal Cancer NSABP Foundation Inc|Merck Sharp & Dohme Corp.|Eli Lilly and Company April 2019 Phase 1
NCT03366155 Recruiting Colorectal Cancer|Liver Metastases|Colorectal Adenocarcinoma|Colorectal Cancer With Hepatic Metastases|Colorectal Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 1 2019 Phase 2
NCT03813784 Not yet recruiting Gastric Cancer|GastroEsophageal Cancer Jiangsu HengRui Medicine Co. Ltd. March 2019 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID